Categories Covered:Managing Long-Term HIV Survivors, HIV Treatments in Development, PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention Methods, HIV Care and Services Outside the US, Adverse Events, Comorbidities, and HIV, Providing Quality HIV Care, Dolutegravir (Tivicay), HIV Epidemiology, First-Line HIV Treatment, Managing Primary/Acute HIV Infection, Managing People Newly Diagnosed With HIV, HIV Care Continuum, HIV Education and Risk Management, HIV Testing, FDA-Approved HIV Medications, Zerit (Stavudine, d4T), HIV in Specific Countries, Ritonavir (Norvir), Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF), HIV Policy and Advocacy, Abacavir (Ziagen), Tenofovir Disoproxil Fumarate (Viread), Pregnancy, Childbirth, and HIV, HIV in Film, TV, and Media, Managing HIV Drug Resistance, HIV Advocates in the Spotlight, Switching or Stopping HIV Treatment, HIV Treatment Strategies, Atazanavir (Reyataz), Raltegravir (Isentress), Darunavir (Prezista), Rilpivirine (Edurant), Cobicistat/Darunavir (Prezcobix), Pediatric HIV Care, Enfuvirtide (T-20, Fuzeon), Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla), Efavirenz (Sustiva, Stocrin), U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Elvitegravir (Vitekta), Meeting the Costs of HIV Care, HIV, Discrimination, and Law, HIV in Books and Publishing, Didanosine (ddI, Videx), Maraviroc (Selzentry, Celsentri), Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi Lo), PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention and Transmission, HIV Advocacy and Activism, Financial Issues, Etravirine (Intelence), PEP (HIV Post-Exposure Prophylaxis), Starting HIV Treatment and Medical Care, HIV and Mental Health Care, Stavudine (d4T, Zerit), Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Cobicistat (Tybost), Atazanavir/Cobicistat (Evotaz)
The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.
Although the move means that more Britons might be able to access free PrEP, this study is also controversial for being seen as a way to delay full government approval.
A fascinating lecture at this year's HIVR4P conference showed how advances in modern scanning technologies can be used to get more accurate information about the first stages of HIV infection and on the ways that HIV drugs are absorbed and distribute...
Several presentations at the 2018 HIV Research for Prevention conference looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.
Preliminary data released by Public Health England show that HIV diagnoses dropped by 17% in 2017 compared to 2016.